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Human Tumor-infiltrating Myeloid 
Cells: Phenotypic and Functional 
Diversity
Louise A. Elliott, Glen A. Doherty, Kieran Sheahan and Elizabeth J. Ryan*
Centre for Colorectal Disease, St. Vincent’s University Hospital, School of Medicine, University College Dublin, Dublin, Ireland
Our current understanding of human tumor-resident myeloid cells is, for the most part, 
based on a large body of work in murine models or studies enumerating myeloid cells 
in patient tumor samples using immunohistochemistry (IHC). This has led to the estab-
lishment of the theory that, by and large, tumor-resident myeloid cells are either “protu-
mor” M2 macrophages or myeloid-derived suppressor cells (MDSC). This concept has 
accelerated our understanding of myeloid cells in tumor progression and enabled the 
elucidation of many key regulatory mechanisms involved in cell recruitment, polarization, 
and activation. On the other hand, this paradigm does not embrace the complexity of 
the tumor-resident myeloid cell phenotype (IHC can only measure 1 or 2 markers per 
sample) and their possible divergent function in the hostile tumor microenvironment. 
Here, we examine the criteria that define human tumor-infiltrating myeloid cell subsets 
and provide a comprehensive and critical review of human myeloid cell nomenclature 
in cancer. We also highlight new evidence characterizing their contribution to cancer 
pathogenesis based on evidence derived from clinical studies drawing comparisons with 
murine studies where necessary. We then review the mechanisms in which myeloid cells 
are regulated by tumors in humans and how these are being targeted therapeutically.
Keywords: tumor microenvironment, monocytes, macrophages, neutrophils, myeloid derived suppressor cells, 
immune cell phenotyping, oncoimmunology
iNTRODUCTiON
Cancer immunotherapy entered a new era with the introduction of immune checkpoint inhibitors. 
Dramatic and durable responses are now observed in patients with previously untreatable tumors. 
However, these remarkable outcomes are not yet achievable in all patients, and some tumor types, 
e.g., microsatellite stable colorectal cancers (CRC), fail to respond to these drugs. In these cases, we 
need further interventions to overcome the immune regulatory context of the tumor microenviron-
ment (TME) and to harness the power of the antitumor immune response. Infiltrating myeloid cells 
are potent regulators of tumor-associated immune suppression, cell invasion, and metastases, and 
targeting of these innate immune cells may be the key to developing new immunotherapies.
In the past decade, with the advent of multiparameter flow cytometry, the identification and 
nomenclature of myeloid cell populations have become increasingly complex. Figure 1 illustrates 
our current understanding of human myeloid cell subsets and the markers that they express in the 
bone marrow, blood, and tissue of cancer patients. It is evident that distinct myeloid cell types may, 
in fact, express similar levels of certain putative lineage-specific markers, e.g., CD11b or CD68. 
FigURe 1 | Continued
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FigURe 1 | Continued 
Overview of human myeloid cells identified in the bone marrow, blood, and tissue of cancer patients. Cancer-associated inflammation upregulates the 
production of myeloid cells from hematopoietic progenitors in the bone marrow. This figure illustrates the network of myeloid cells that have been identified in the 
blood and tumor tissue in human cancer. Cell surface markers expressed by the various myeloid cell types are listed portraying the huge degree of phenotypic 
similarity between the cell subsets. The thick curved black line depicts a pathway of cell differentiation that has been suggested but has not yet been proven.
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A further important consideration is the fact that expression 
of many myeloid lineage markers can change upon exposure 
to inflammatory mediators present within tumors. One impor-
tant illustration of this is the striking resemblance that human 
tumor-resident myeloid-derived suppressor cells (MDSCs) have 
with human peripheral blood neutrophils; both cell subsets are 
CD33+CD11b+HLA-DR− and arginase-1+ (Arg-1). In fact, many 
tumors are highly infiltrated with neutrophils (as identified by 
their distinct morphology). Considering that no single marker 
can accurately differentiate between the two subsets, it is plausible 
to suggest that cells often designated as MDSC may also include 
a significant proportion of alternatively activated neutrophils. 
Thus, tumor-infiltrating MDSC can be viewed as a modified ver-
sion of a neutrophil that has adapted to their environment and 
taken on an immunosuppressive function. To improve consist-
ency among studies and minimize bias and confusion, we need 
to begin to move away from an oversimplified M1/M2/MDSC 
nomenclature. We need to consider adopting, where possible, a 
more complete description of myeloid cells based on a thorough 
assessment of lineage markers and classifications based on cell 
origin in combination with activation markers. Where this is not 
feasible, e.g., when only immunohistochemistry (IHC) analyses 
are practical, more careful data interpretation is needed.
A further layer of complexity in fully understanding the role of 
human myeloid cells in tumor biology is the degree of variation 
observed between individual patients and different tumor types. 
Progress has been made on defining key features that will enable 
the classification of tumors into specific subtypes allowing for 
better treatment stratification (e.g., HER2- or ER-positive breast 
cancer) (1). In CRC, it is clear that tumors displaying mismatch 
repair instability have higher cytotoxic lymphocyte infiltrates 
that correlate with a better prognosis (2). However, the relation-
ship between myeloid cell subsets and different tumor subtypes 
remains to be explored.
It is difficult to ascribe precise functional roles for each of these 
individual myeloid cell subtypes in cancer progression. Although 
studies have shown that evaluation of the myeloid cell infiltrate 
has prognostic value (3–6), it is not yet known if these cells are a 
driver of the multistep process of tumorigenesis. To appreciate the 
importance of myeloid cells in tumor progression, we must under-
stand how they interact within the TME. For example, dissecting 
the concerted interactions between myeloid cells and genetically 
altered cells that regulate the expression of other cancer hallmarks 
(cellular energetics, proliferative ability, angiogenesis, invasion, 
metastasis, and inflammatory signature) will help elucidate how 
these cells respond and evolve during tumorigenesis.
Once we understand the complexity of the mechanisms 
involved in myeloid regulation and how they impact on tumor 
progression, we can develop better therapeutic strategies that 
target tumor–myeloid interactions.
MYeLOiD CeLLS iN HUMAN CANCeR: 
OveRview OF DATA geNeRATeD BY iHC
Our understanding of the role that myeloid cells play in human 
cancer comes from evidence provided by retrospective cohort 
studies employing IHC where myeloid cells are identified by 
the expression of one or at most two markers, most commonly 
CD68 or CD163. This has led to a significant body of work dem-
onstrating that the presence of tumor-associated macrophage 
(TAM) infiltrates correlate with poor patient prognosis. This is 
true across a variety of tumor types including breast, bladder, 
and ovarian cancer (3–6). Yet in other studies, a high degree 
of macrophage infiltration has been associated with improved 
patient outcome (7). Similarly, neutrophil influx as characterized 
by their unique morphology is associated with poor prognosis 
(8) and treatment failure in hepatocellular carcinoma (HCC) (9). 
Although these studies are informative, myeloid biology within 
the TME remains poorly understood, as this type of analysis 
cannot discriminate between different cellular activation states 
or give conclusive evidence regarding their function. Therefore, 
we need to use a more holistic approach, incorporating different 
technologies, e.g., CyTOF and multiparameter flow cytometry 
with next-generation deep sequencing to fully understand the 
role of different myeloid cell subsets in the regulation of antitu-
mor immunity within different tumor environments. These types 
of studies will consolidate the emerging evidence that myeloid 
cells play an important role in tumor progression by facilitating 
angiogenesis and invasion (10).
TUMOR-iNFiLTRATiNg MYeLOiD  
CeLL SUBSeTS
The majority of studies investigating the phenotype and function 
of human myeloid cells within the TME have classified these 
cells into one of the following categories: (i) TAMs, (ii) Tie-2-
expressing monocytes (TEMs), (iii) polymorphonuclear (PMN) 
leukocytes (neutrophils), or (iv) MDSCs. Here, we review the 
different phenotypes and functions ascribed to these cell types 
within human tumors.
TUMOR-ASSOCiATeD MACROPHAgeS
Macrophages are terminally differentiated cells that reside in 
all tissues. They are most commonly derived from circulating 
monocytes and are instrumental in the orchestration of tissue 
homeostasis, immune surveillance, and inflammation (11).
Many studies investigating the importance of macrophages in 
cancer are based on the concept that two main functional pheno-
types for macrophages exist, the M1 (classical) and M2 (alterna-
tive) phenotype (4, 5). The M2 phenotype is, for the most part, 
TABLe 1 | immunophenotyping of tumor-infiltrating myeloid cells in human cancers.
Tumor type Markers used Subsets identified Reference
Bladder 
(urothelial 
carcinoma)
CD11b, HLA-DR, CD206, CD68, 
CCR8
CD11bhiHLA-DRloCD206+CCR8+ (17)
Bladder CD45, CD11b, HLA-DR, CD33, 
CD15
 1. CD11bhiHLA-DRhi
 2. CD11bhiCD15hi
(18)
Breast (ascites) CD45, CD11b, HLA-DR, CD11c, 
CD14, CD16, CD1c, CD1a
 1. CD45+HLADRhiCD11chiCD16+CD1c−
 2. CD45+HLADRhiCD11chiCD16−CD1c+
(Both subsets express CD11b, CD206, and CD14)
(19)
Colorectal CD14, CD169, CD163, CD206 CD14+CD169+CD163+ (20)
Colorectal CD45, CD11b, CD11c, CD68, CD32, 
CD64, HLA-DR, CD80, CD86
CD45+CD11b+CD11c+CD68+CD32+CD64−HLA-DR−CD80−CD86− (21)
Colorectal CD33, HLA-DR, CD11b CD33+CD11b+HLA-DR− (22)
Gastrointestinal 
stromal tumor
CD11b, CD14, CD11c, CD86, CD64, 
CD163, HLA-DR, CD45
CD45+ CD11b+HLA-DRhi CD11c+CD14+CD86+ (16)
Head and neck 
squamous cell 
carcinoma
CD11b, CD14, HLA-DR, CD33, 
CD34, CD11b, CD14, CD15
CD11b+CD14+HLA-DRlo CD33+ CD34+ CD15+ (15)
Lung CD11b, CD15, CD66b, MPO, 
arginase, CD62L, CD54, CXCR2, 
CCR7, CXCR3, CXCR4
 1. CD11b+CD15+CD66b+ MPO+ Arg+ CD62lo CD54+ CXCR2lo CCR7+ CXCR3+ CXCR4+
 2. CD11b+ CD15+
(23)
Melanoma Lin-1−, CD11b, CD14, CD15  1. CD11b+ CD14+HLA-DRhi
 2. CD11b+ CD14− CD15intHLA-DR+
 3. CD11b+ CD14− CD15hiHLA-DR+/lo
(24)
Mesothelioma CD14, CD163, CD206, HLA-DR, 
CD80, CD86, interleukin (IL)-4α
CD14+ CD163+ CD206+ HLA-DR+ IL-4α+ (25)
Ovarian (ascites) CD45, CD11b, HLA-DR, CD11c, 
CD14, CD16, CD1c, CD1a
 1. CD45+HLADRhiCD11chiCD16+CD1c−
 2. CD45+HLADRhiCD11chiCD16−CD1c+
(Both subsets express CD11b, CD206 & CD14)
(19)
Ovarian (high 
grade)
CD2, CD3, CD4, CD15, CD45, 
CD16, CD19, CD33, CD133
CD45+CD33+HLA-DRint CD15−CD16− (26)
Pancreatic Lin-1, HLA-DR, CD33, CD11b, 
CD15, CD14
 1. Lin-1−HLA-DR−CD33+CD11b+CD15+
 2. Lin-1−HLA-DR−CD14+
(27)
Pancreatic CD45, CD14, CD15, CD11b, HLA-
DR, CSF-1R
 1. CD45+CD11b+CD14+HLA−DRlo
 2. CD45+CD11b+CD15+
(28)
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associated with cancer progression and worse overall survival in 
cancer patients (3, 4). IHC to detect cells expressing CD68, CD86 
(M1), or CD163 and CD206 (M2) is frequently used to quantify 
and classify tumor-infiltrating macrophages (12). However, TAMs 
are not simply cells with these restricted “M1” or “M2” pheno-
types and associated functions. In reality, the tumor macrophage 
compartment is more diverse and heterogeneous, with cells dis-
playing considerable plasticity driven by environmental cues. A 
recent study generated a framework that showed that macrophage 
activation states go beyond the current M1 and M2 polarization 
model and represent a spectrum (13). This framework recognizes 
that macrophages are capable of adjusting to meet the functional 
requirements of their environment. One such example is the 
intestine, where macrophages are characterized as partially inert 
cells allowing them to respond to the constant exposure of dietary 
and commensal antigen in a controlled manner (14).
A number of research groups have examined the phenotype 
of tumor-infiltrating myeloid cells in different tumor types using 
multiparameter flow cytometry. In Table  1, we summarize a 
number of these recent studies. Here, we document the cell 
surface markers employed by each study and the main myeloid 
cell subset found in the tumor tissue. It is evident that there is 
huge variability in the myeloid cells found in the different tumor 
types. For example, Vasquez-Dunddel et al. found that a CD14hi 
HLA-DRlo subset resided in the tumor tissue in head and neck 
squamous cell carcinoma (HNSCC), whereas in gastrointestinal 
stromal tumors, a CD14hi HLA-DRhi subset was identified (15, 
16). The discrepancies between these two studies may reflect the 
transient nature of HLA-DR expression especially when you take 
into consideration the very complex and variable microenviron-
ments associated with different tumor types. However, it could 
be argued that these HLA-DRlo cells could represent a subset of 
M-MDSCs (discussed in the section below) as tissue-resident 
macrophages are classically HLA-DR positive.
Yet a common finding also emerges that most tumor 
types are highly infiltrated with CD11b+ cells (Table  1). Not 
surprisingly the CD11b-expressing cell population is highly 
heterogeneous composed of both monocytic and granulocytic 
FigURe 2 | Suggested gating strategy for the identification of tumor-infiltrating myeloid cells in humans. To dissect the main infiltrating myeloid cells, we 
propose a 12 color flow cytometry panel and progressive gating strategy. Gating on the CD45+ population identifies the leukocyte population. Within the HLA-
DRhiCD11chi population, tumor-associated macrophages (TAMs) can be distinguished from DCs based on CD14+CD64+ expression. The CD11bhiCD15hi population 
identifies tumor-infiltrating neutrophils. CD66b is used to confirm the identity of neutrophils. Tumor-associated neutrophils (TANs) express CD33 and arginase at 
varying levels. It is important to note that low levels of CD64 and CD14 can be expressed on TANs, whereas TAMs can express low levels of CD15. Eosinophils are 
CD15int and CD16lo. It is important to use the appropriate controls such as fluorescence minus one controls and normal or uninvolved tissue where possible.
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cells. Unfortunately, there is very little uniformity among the 
methodologies employed by these studies. A proportion of stud-
ies report that the CD11b+HLA-DR+ subset co-expresses mono-
cyte and macrophage-associated markers CD14, CD68, CD11c 
(21), or M2-associated markers such as CD206 (17). However, 
others report that the CD11b+ cells represents a neutrophil-like 
cell based on their high CD15 expression (18, 27). Complicating 
matters more, in HNSCC, this subset expressed both markers 
CD14 and CD15, suggesting that these markers are not suitable 
for the delineation of macrophages and neutrophils in all tissues, 
particularly in the inflammatory TME (15, 29).
Interestingly, CD163+ and CD206+ macrophages derived 
from gastrointestinal tumors and ovarian ascites, respectively, 
possessed the ability to stimulate T cell responses (16, 19). As a 
consequence, these studies concluded that these cells were func-
tionally equivalent to M1 or inflammatory macrophages, despite 
the expression of M2 like markers. Collectively, these studies 
reinforce the idea that the definition of a myeloid cell’s putative 
function based solely on their expression of cell surface markers 
is potentially flawed.
Unfortunately, for the most part, the studies listed in Table 1 
did not use sufficiently broad panels of antibodies to characterize 
more than one myeloid cell subset in any single data set. As a 
result, it is unclear how each of the individual cell subsets relates 
to one another within the same tumor. More importantly, the 
co-existence of multiple cell subsets co-expressing one or more 
markers cannot be ruled out. Considering tumor-infiltrating 
lymphocytes are an important positive prognostic and predictive 
marker in many cancer types, it would be interesting to deter-
mine how myeloid cell infiltrates correlate with concomitant 
lymphocyte infiltration (30). Differences in experimental design 
and antibody panels also make adequate comparisons between 
studies and across the different cancer types difficult. In mice, 
researchers have developed detailed flow cytometry panels and 
progressive gating strategies to accurately profile the CD45+ cell 
compartment of the tumor (31, 32). A concerted effort is needed 
to harmonize experimental design, gating strategies, and the cell 
surface markers employed so that the complete picture of the 
myeloid cell landscape within human tumors emerges, and we 
can understand how myeloid cell biology evolves with cancer 
progression. In Figure 2, we present a suggested flow cytometry 
gating strategy that allows for the identification of myeloid cells 
within tumor tissue.
Tie-2-eXPReSSiNg MONOCYTeS
Tie-2-expressing monocytes that were first described in a murine 
model of glioma by De Palma et al. are a monocyte subset equipped 
with proangiogenic activity (33, 34). TEMs are predominantly 
part of the CD14+CD16+ monocyte subset and express elevated 
levels of the proangiogenic molecules vascular endothelial 
growth factor (VEGF), matrix metallopeptidase (MMP) 9, and 
insulin growth factor-1 compared to Tie-2− monocytes (35, 36). 
As expected, there is an increased frequency of TEMs in tumor 
tissue (30–80%) compared to adjacent normal tissue in patients 
with either renal cell carcinoma (RCC) or HCC (37, 38). This sug-
gests that TEMs accumulate in tumor tissue fueling the growth 
of blood vessels that help to meet the functional demand of the 
growing tumor. However, beyond this, our understanding of the 
role of TEMs in tumor pathogenesis is virtually non-existent.
6Elliott et al. Solid Tumor-Infiltrating Myeloid Cells
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Tie-2-expressing monocytes are also present in the peripheral 
blood of both healthy individuals and cancer patients (39, 40). 
It has been hypothesized that the presence of circulating TEMs 
could be a potential prognostic cellular biomarker for cancer. In 
keeping with this, TEM frequency was significantly increased 
in the blood of patients with HCC, enabling the differentiation 
of HCC from chronic liver disease (38). However, two further 
studies showed that TEM frequencies in the peripheral blood did 
not differ significantly between patients with CRC and healthy 
individuals (40, 41). Whether detection of circulating TEMs will 
have a clinically useful role in the management of cancer patients 
in particular settings remains to be determined in multicenter 
validation studies.
PMN LeUKOCYTeS (NeUTROPHiLS)
Neutrophils are the body’s primary line of defense against invad-
ing pathogens, and their importance in cancer immunology was 
highlighted by the combined observations that a high blood 
neutrophil to lymphocyte ratio (42, 43) and tumor-infiltrating 
neutrophils (detected by IHC) are independent prognostic factors 
for tumor recurrence (4, 8, 44). The importance of neutrophils in 
tumor progression was further confirmed in a study employing 
CIBERSORT, a computational method for extrapolating leukocyte 
cells (45). Twenty-two immune cell subset signatures across 25 
cancer histologies were examined. Remarkably a PMN-associated 
gene signature materialized as the most significant adverse 
cancer-associated prognostic factor (45). It is possible that some 
neutrophils are involved in preventing cancer progression, and 
in support of this, Amicarella et al. found that neutrophil infiltra-
tion correlated with a favorable outcome in CRC (46). Similar to 
the macrophage studies, these results provide correlative but not 
causative links between neutrophils and tumor growth or control. 
Therefore, the role neutrophils play in tumor biology still requires 
clarification in all settings and tumor types.
Neutrophils are considered a heterogeneous population of cells. 
Similar to the macrophage paradigm, neutrophils are reported to 
have dichotomous antitumor (N1) and protumor (N2) functions 
in mice (47). Evidence suggests that transforming growth factor 
(TGF)-β within the TME is largely responsible for neutrophil 
polarization, and inhibition of TGF-β favors the accumulation 
of N1 tumor-associated neutrophils (TANs). In mice, N1 and 
N2 TANs can only be distinguished from each other based on 
function. Naturally the N1-protumor phenotype secretes more 
immunoactive cytokines, expresses lower levels of Arg-1, and 
possesses greater ability to kill tumor cells (47). The majority of 
human studies have investigated blood neutrophil alterations in 
cancer patients. In HNSCC, patient’s isolated neutrophils showed 
reduced inducible reactive oxygen species (ROS) production 
and decreased spontaneous apoptosis (48). In bladder cancer, 
neutrophils exhibited impaired killing (49), whereas neutrophils 
from patients with oral cavity cancer secreted higher levels of 
VEGF (50) and diminished levels of soluble tumor necrosis 
factor (TNF)-related apoptosis-inducing ligand (51). Although 
informative, future studies are needed to unravel the fundamental 
antitumor and protumor interactions between neutrophils and 
malignant cells within the TME. One interesting study identified 
a CD10+ TAN (CD11b+CD15+) predominantly located at the 
invasive front of CRC tumors. This subset strongly correlated 
with tumor budding and TGF-β expression (52). Tumor buds are 
a small group of cancer cells (<5) thought to have undergone epi-
thelial mesenchymal transition (EMT) changes and are an adverse 
prognostic factor (53). The discovery that this subset correlates 
with TGF-β supports the idea that this subset may represent the 
N2 population. In contrast, a recent study identified an antigen-
presenting cell like “hybrid neutrophil” in early-stage human lung 
cancer defined as CD11b+Arg-1+CD66b+CD15+HLA-DR+CD14+ 
(54). This subset originated from an immature progenitor in 
response to tumor-derived interferon (IFN)-γ and granulocyte 
macrophage colony-stimulating factor (GM-CSF) and stimulated 
antitumor T cell responses. Apart from these studies, the exact 
functional attributes of neutrophils within the TME have yet to 
be fully explored in humans. Akin to the macrophage paradigm, 
neutrophil function and phenotype are most likely transient, 
constantly changing in response to their evolving environment.
One of the most controversial issues in TAN studies is their 
complicated relationship with MDSCs. Both subsets share 
phenotypic and functional similarities, which will be further 
explored in the next section.
MYeLOiD DeRiveD SUPPReSSOR CeLLS
Myeloid-derived suppressor cells are defined by their ability to 
suppress T cell responses and are a heterogeneous population 
of immature myeloid cells. MDSC were originally characterized 
in tumor-bearing mice, where they are classically divided into 
monocytic (M) (CD11b+/Ly6C+) MDSC and PMN (CD11b+/
Ly6G+) MDSC (55). The consensus is that MDSCs are hemat-
opoietic progenitor cells generated in the bone marrow that fail 
to undergo terminal differentiation to mature monocytes or 
neutrophils before being released into the circulation (56). As a 
result, these cells are greatly expanded under certain pathological 
conditions, and as their name suggests, their highly suppressive 
activity is their defining feature.
In man as in mice, there are two main MDSC subsets: mono-
cytic (CD14+) MDSC and PMN (CD15+) MDSC. Classically, 
human MDSCs are described as lineage negative cells that 
co-express CD11b and CD33 but lack HLA-DR. Additional 
functional markers have also been attributed to MDSCs such as 
Arg-1, indoleamine 2, 3-dioxygenase (IDO1) ROS, and nitric 
oxide synthase, which all mediate immunosuppression (56).
The complexity of human MDSC characterization in patient 
samples is summarized in Table 2. It is clear from the literature 
that human tumors exhibit a great disparity in the distribution 
and phenotype of both PMN-MDSC and M-MDSC. The major-
ity of the studies report an increase in the number of MDSCs 
in cancer patients’ blood when compared to healthy controls; 
however, the frequencies and phenotype reported differ greatly. 
For example, in bladder cancer, Uan et al. found that nearly half 
of circulating monocytes expressed low levels of HLA-DR (57), 
whereas in breast cancer, all CD14+ monocytes in patients’ blood 
expressed low HLA-DR (58). Similarly, in non-small cell lung 
cancer (NSCLC), two different studies identified PMN-MDSC 
(CD11b+CD15+CD33+) as the dominant MDSC subset in the 
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blood of patients albeit at different frequencies (59, 60). It is not 
known whether this variability is the result of tumor-specific 
derived factors or a consequence of experimental design and 
methodology. The accelerating interest in MDSCs accompanied 
by the large body of information generated has led to confusion 
and inconsistency in MDSC nomenclature. To help address this 
problem, Bronte et al. developed a logical framework for defining 
the heterogeneous population of MDSCs in both humans and 
mice providing minimal phenotypic, molecular, and functional 
requirements (61). This gating strategy has been optimized 
in the peripheral blood of patients and controls, but further 
validation for the analysis of tumor-infiltrating MDCS is still 
required. It would be valuable to combine Bronte’s strategy with 
the one proposed in Figure  2 to gain a clearer understanding 
of how the different myeloid cell types co-exist within tumors. 
With the incorporation of these additional lineage and activation 
markers, a greater appreciation for the heterogeneous nature of 
tumor-infiltrating leukocytes can be achieved. Bronte et  al. 
identify three subsets of MDCS in PBMC: M-MDSC (CD14+ 
HLA-DRlo), e-MDSC (CD33+lin−HLA-DR−), and PMN-MDSC 
(CD14−CD15+CD11b+). Performing this analysis on PBMC 
allows for the depletion of neutrophils from the sample. As a 
result, it can be assumed that using the combination of mark-
ers (CD11b, CD14, and CD15), PMN-MDSC can be accurately 
identified. However, in tissue, density gradient centrifugation is 
not usually performed; as a consequence, the markers CD11b, 
CD14, and CD15 are not sufficient as they are also expressed 
by neutrophils. Our panel includes CD16 and CD66b, which 
are classical neutrophil markers, and using this in combination 
with SSC profiles and CD11b, CD14, and CD15 should confirm 
the identity of the cells. We also included markers CD11c and 
HLA-DR that can classify dendritic cells and TAMs in combi-
nation with CD14, CD64, and CD11b. This allows the parallel 
examination of MDSC and TAMs in one sample. Finally, in the 
pro-inflammatory environment of tumor tissue, granulocytes 
may upregulate CD14. Therefore, the use of CD14 and HLA-DR 
alone may not be sufficient markers to identify M-MDSC within 
tissue. The addition of granulocyte markers will allow the accu-
rate detection of M-MDSC.
The expansion of PMN-MDSC is much greater in tumor-
bearing mice compared to that of the monocyte subset (77). 
However, it is unclear whether the same finding is mirrored in 
humans as the majority of studies have only characterized one 
subset. In fact only two studies have carried out a comprehensive 
phenotype of both MDSC subsets present in the blood of patients 
with NSCLC (59) and breast cancer (58). Interestingly, both 
studies found higher frequencies of PMN-MDSC compared to 
M-MDSC although different phenotypes are reported by the two 
studies. The former study in NSCLC identified PMN-MDSC as 
CD15+, whereas Yu et al. found that PMN-MDSC lacked CD15 
expression but were CD66b+.
Only a few studies have evaluated the frequency and phenotype 
of tumor-infiltrating MDSCs (5, 15, 22, 26, 58, 66, 71). Because 
of the variation in experimental design, it is hard to determine 
which MDSC subset dominates in the tumor tissue. In both HCC 
and HNSCC, MDSCs defined as CD14+ with low HLA-DR were 
detected in the tumor tissue. However, in HNSCC, the subset also 
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co-expressed CD15. This finding emphasizes how defining these 
cells based on a limited number of markers does not allow accu-
rate delineation of the origin of these cells. The systematic study 
of both MDSC subsets in tumor tissue and patients’ peripheral 
blood is urgently required to better understand how these cell 
populations fluctuate as the tumor progresses.
The relationship between PMN-MDSC and neutrophils is 
another issue that remains unclear. It has been proposed that 
PMN-MDSCs may be a small naturally occurring subpopula-
tion of granulocytes (78). The observation that the frequency of 
circulating PMN-MDSC (CD15hiCD11bhiCD33hiCD14−) did not 
differ between cancer patients and healthy controls, with a low 
frequency of less than 1%, supports this hypothesis. In addition 
to using the specific markers mentioned earlier, MDSCs can also 
be identified using the neutrophil-associated markers, CD66b 
and CD15 (27, 76). For example, in RCC, MDSCs isolated from 
peripheral blood expressed similar levels of CD15, CD11c, and 
CD33 compared to neutrophils. The only phenotypic difference 
identified was high levels of CD11b and CD66b and low levels of 
CD62L and CD16 expressed by MDSCs, fitting the phenotype of 
an activated neutrophil (76). This study clearly demonstrates the 
strong phenotypic similarities between MDSC and neutrophils 
and should make us question the rationale for studying MDSCS 
as a unique entity separate to granulocytes.
In humans, one of the key defining features that can help 
distinguish MDSCs from mature neutrophils is their lower 
density. As a consequence, PMN-MDSCs can be detected in the 
mononuclear cell fraction of peripheral blood. Recently, a distinct 
low-density neutrophil (LDN) subpopulation was detected along 
with the expected “normal” high-density neutrophil (HDN) in 
the blood of cancer patients (78). Interestingly, the authors’ report 
that the LDN population consisted of two distinct neutrophil 
subsets made up of immature (band) and mature (segmented) 
neutrophils. Similar to the study mentioned previously, the 
LDN subset had a greater forward scatter and expressed higher 
levels of CD11b and CD66b when analyzed by flow cytometry. 
Intriguingly, in agreement with the N1–N2 paradigm, HDNs 
were capable of becoming LDNs in a TGF-β-dependent manner, 
a switch that was accompanied by a gain of immunosuppressive 
properties (78).
Recent data also demonstrate that band neutrophils possess the 
ability to “transdifferentiate” into monocytic cells upon recruit-
ment to inflammatory sites. The acquisition of monocyte-like 
characteristics was dependent on MKK6-p38 activation driven 
by the pro-inflammatory cytokines such as interleukin (IL)-1β, 
TNF-α, and GM-CSF (79). There are significant challenges to 
studying MDSC including their lack of unique surface markers 
and the plasticity these cells exhibit, particularly in response to 
inflammation within the TME. A more methodical approach to 
identifying MDSCs needs to be established if we are to define 
their role in tumor progression and enable development of suc-
cessful therapies targeting these cells. Furthermore, important 
and unresolved questions remain: Are MDSCs a separate entity 
to granulocytes with a unique ontogeny, phenotype, and func-
tion? Or are they simply a neutrophil that represents a different 
functional state induced by the TME? If so, should we reconsider 
the nomenclature of these cells and simplify our approach to 
defining the cell according to their origin?
ReCRUiTMeNT AND ACTivATiON OF 
MYeLOiD CeLLS wiTHiN THe TMe
The accumulation of genetic alterations that cause neoplasia can 
elicit an intrinsic inflammatory response. Complex cytokine and 
chemokine gradients are established that recruit and shape the 
leukocyte infiltrate, of which myeloid cells constitutes a large 
proportion. Although the key components that govern myeloid 
cell recruitment and activation within different TMEs are yet to 
be fully defined, understanding how these processes are regulated 
will greatly accelerate the identification of new therapeutic tar-
gets. Here, we outline the most significant findings reported to 
date and highlight key areas for future study.
Mechanisms of Myeloid Cell Recruitment
Among the chemotactic factors, chemokine (C-C Motif) ligand 
2 (CCL2) is considered to be a key player in the recruitment of 
monocytes to the tumor, and the CCL2-CCR2 axis has been 
proposed as a new therapeutic target (80). Inhibition of CCL2-
CCR2 signaling in tumor-bearing mice blocked the recruitment 
of inflammatory monocytes to the site of lung metastasis and 
prolonged their survival (81). However, the mechanisms involved 
in monocyte recruitment and what subsets are preferentially 
recruited to the tumor are not fully known in humans. There is 
some evidence demonstrating that high levels of CCL2 expres-
sion by cancer cells correlates significantly with TAM infiltration 
of tumors and poor prognosis for patients (82–84). It is important 
to note that a striking heterogeneity of CCL2 expression levels in 
human tumors has been reported. For example, reduced levels 
of CCL2 were detected in liver cancer and metastatic prostate 
cancer when compared to normal adjacent tissue, whereas higher 
levels were detected in breast cancer and oral squamous cell 
carcinoma (85). There is conflicting evidence regarding the exact 
source of CCL2 within the tumor. Zhou et al. identified TANs 
as the primary source of CCL2 and CCL17 in HCC driving the 
recruitment of macrophages and CCR4+ Treg cells, respectively, 
to the tumor site (9) In contrast, Spary et al. found that fibroblast-
derived CCL2 promoted the migration of monocytes in prostate 
cancer (86).
Also, it is not clear from these studies whether CCL2 is solely 
responsible for the accumulation of monocytes in the tumor. 
There is a great degree of redundancy and complexity within 
the human chemokine/chemokine receptor system, and this 
must be taken into account the design of therapies targeting 
this pathway. For example, CCL2 was found to induce CCL3 
expression in both human and murine macrophages, which trig-
gered a CCL3-CCR1 signaling cascade in monocytes, essential 
for efficient metastasis in a mouse model (87). At present, a 
monoclonal antibody directed at CCL2 is in development for 
the treatment of patients with advanced solid tumors (trials are 
listed in Table 3).
Several studies have described TEMs as being CCR5, CCR4, 
and CXCR3 positive, which suggest that they translocate in 
TABLe 3 | Summary of novel immunotherapies targeting myeloid cells.
Target Drug name Stage of 
development
Clinical trial 
identifier
Cancer subtype Reference
Arginase-1 CB-1158 Phase 1 NCT02903914 Solid tumora
CCL2 Carlumab (CNTO 888) Phase 1 NCT00537368 Solid tumor (88)
Phase 1 NCT01204996 Solid tumor
Phase 2 NTC00992186 Prostate (89)
CCR2 MLN1202 Phase 2 NCT01015560 Bone metastases
CSF-1R BLZP45 Preclinical GBM (90)
BLZP45 Preclinical GBM (91)
Colony-stimulating factor-1 neutralizing 
antibody
Preclinical Pancreas (92)
Plexidartinib (Plx3397) Phase 2 NCT01349036 GBM (93)
NCT02452424 Melanomab
Emactuzumab (RG7155) Phase 1 NCT01494688 Solid tumor (94)
Ly3022855 (IMC-CS4) Phase 1 NCT01346358 Solid tumor
Phase 1 NCT02718911 Solid tumorc
Indoleamine 2, 
3-dioxygenase (IDO1)
Indoximod Phase 1
Phase 1/2
NCT01191216
NCT02052648
Solid tumor
Glioma
(95)
Phase 1/2 NCT02073123 Melanomad
Phase 1/2 NCT02077881 Pancreatic
Phase 1b/2 NCT0246036 Non-small cell lung cancer 
(NSCLC)
IDO1 peptide vaccination NCT01219348 NSCLC (96)
CXCR2 Pepducin Preclinical Pancreatic (97)
Preclinical RMS (98)
Reparixin Phase 1 NCT02001974 Breast
Phase 2 NCT02370238 Breast
AZD5069 Phase 1b/2 NCT02499328 SCCHNe
Interleukin (IL)-8 HuMax-IL-8 (MDX 018) Phase 1 NCT02536469 Advanced solid tumor
acombination with nivolumab.
bcombination with pembrolizumab.
ccombination therapy with Durvalumab.
dcombination with checkpoint inhibitors.
ecombination with Durvalumab.
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response to CCL3, CCL4, and CCL5, which are reported to be 
present within the TME (99–101). Furthermore, monocytes iso-
lated from RCC patients revealed a distinct transcriptional profile 
compared to healthy control monocytes with significant increases 
in CCL3, CCL5, and CCL20 observed in the former (102). In 
ovarian cancer, CXCL12 promoted the recruitment of MDSCs 
in a prostaglandin E2 (PGE2)-dependent manner (70). However, 
deciphering the exact role of other chemokines involved in the 
recruitment of myeloid cells and effect on local immune response 
remains to be properly investigated in human cancer.
The TME is highly enriched with a variety of growth fac-
tors that facilitate the bidirectional communication between 
tumor epithelium and tumor stroma. Multiple growth factors 
are now emerging as potential TME-targeted therapies, includ-
ing colony-stimulating factor-1 (CSF-1). CSF-1 is a principle 
growth factor involved in macrophage survival, differentiation, 
and recruitment (103). In an experimental model, inhibition of 
M-CSFR signaling impaired the extravasation and recruitment 
of monocytes into the tumor (104), whereas overexpression of 
CSF-1 in wild-type mice accelerated tumor progression (105). In 
humans, CSF-1 is widely expressed in ovarian, breast, and, renal 
prostate cancer and correlates with TAM infiltration and disease 
progression (106–108). Currently, Plexxikon (www.plexxikon.
com) among others are developing CSF-1 inhibitors for a variety 
of cancers (summarized in Table  3). However, the blocking of 
CSF-1/CSF-1R may be limited as its efficacy can be dampened 
with the upregulation of immune checkpoint inhibitors such 
as programmed death ligand-1 (PD-L1) in a pancreatic cancer 
model (92). Targeting PD-L1 as a standalone treatment is now 
FDA approved for advanced melanoma and NSCLC, albeit it is 
only successful in approximately 34% of patients (109). Thus, 
combination therapy may be a more effective approach for 
patients who show no or minimal response to checkpoint inhibi-
tors. In addition to its chemotactic potential, CSF-1/CSF-1R can 
enhance the protumor function of TAMs by modulating their 
cytokine signature, enriched with VEGF, TGF-β, and MMPs. 
Thus, the blockade of CSF-1/CSF-1R has a dual effect that may 
also reprogram immunosuppressive TAMs in the TME to sup-
port a more robust cytotoxic T cell response.
The TME is also enriched with other chemokines and cytokines 
that influence neutrophil recruitment to the tumor including 
granulocyte colony-stimulating factor (G-CSF). G-CSF is a 
cytokine that controls the production, differentiation, and func-
tion of granulocytes. IL-17A, a cytokine enriched in the tumor 
11
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tissue, fostered G-CSF-mediated neutrophilia and G-CSF-driven 
emergency myelopoiesis (110). Interestingly, in CRC, Th17 cells 
recruited CD16+ MPO+ neutrophils in an IL-8-dependent man-
ner (46). IL-8 is abundantly expressed by both normal and cancer 
tissue albeit at much higher levels in the latter and is associated 
with a poor prognosis in RCC (92). A more recent study, however, 
showed that IL-8 serum concentration correlated with tumor 
burden and stage in numerous cancers (111). Local production of 
IL-8 creates a chemotactic gradient that induces the recruitment 
of neutrophils, monocytes, and MDSC (62) via the chemokine 
receptors CXCR1 and CXCR2 (112). In a model of rhabdo-
myosarcoma, the blocking of CXCR2 prevented the migration 
of MDSC in to the TME, and interestingly, it also increased the 
efficacy of PD-1 targeting antibodies (98). Considering multiple 
immunosuppressive drivers are at play within the TME, targeting 
one pathway will most likely result in the activation of an alterna-
tive compensatory pathway. Thus, the synergistic effect observed 
here confirms that combination therapy targeting the TME will 
most likely be a more effective alternative treatment strategy for 
cancer patients. Consequently, monoclonal antibody therapy 
against IL-8 is now in the pipeline as a potential complementary 
targeted therapy to T cell-directed antibodies (Table 3).
Mechanisms of Myeloid-Mediated 
Suppression
Mounting evidence indicates that the TME can alter myeloid cells 
converting them into potent immunosuppressive cells. In recent 
years, greater efforts have been made, and now researchers are 
starting to investigate whether these mechanisms are at play in 
human cancers. For example, our group has shown that tumor-
conditioned media generated from human colorectal tumor 
explants can modulate the phenotype and function of human 
monocyte-derived DC (113). It is crucial that we understand the 
interaction between myeloid cells and the TME for us to develop 
and optimize the appropriate therapeutic targets. As a result, 
several key pathways have been identified that are now showing 
promising results in clinical trials.
iNDOLeAMiNe 2, 3-DiOXYgeNASe
Indoleamine 2, 3-dioxygenase has been identified as a signifi-
cant mediator of immune suppression in the TME. IDO1 is an 
immunomodulatory enzyme that catalyzes the breakdown of 
tryptophan to kynurenine rendering effector cells inactive (114). 
Moreover, the production of kynurenine may induce the expan-
sion of Foxp3+ regulatory T cells in certain tumors (57, 114). 
The molecular mechanisms involved in the regulation of IDO1 
expression are still not clear, but CCL20 (114) and the transcrip-
tion factor, signal transducer and activator of transcription 3 
(STAT3) (58), have been implicated. Although there is no IDO1 
inhibitor currently approved for use in humans by the FDA, there 
are a few preclinical studies emerging that have investigated the 
inhibition of IDO1 as a potential TME target. The inhibition of 
IDO1 alone has failed to suppress tumor growth. However, com-
binational regimes with multiple chemotherapeutics have shown 
promising results in several phase 1 clinical trials (Table 3). For 
example, two thirds of patients with refractory solid malignancies 
who received 200 mg indoximod per day experienced objective 
responses or disease stabilization (95). Another promising trial 
found that IDO1 targeting peptide-based vaccine in combination 
with standard of care chemotherapy prolonged disease stabiliza-
tion in nearly 50% patients with NSCLC (96).
ARgiNASe-1
Arginase-1 is an enzyme that metabolizes l-arginine to l-orni-
thine and urea (115). l-Arginine depletion by enzymatic activity 
of Arg-1 is probably one of the most important mechanisms 
employed by MDSCs to mediate local immune suppression in 
the tumor (116). Several human studies have shown that MDSCs 
suppress autologous T cell proliferation and IFN-γ production 
(Table 2), and the depletion of MDSC completely reversed this 
inhibitory effect (5, 57, 58, 63, 64, 66, 67).
To explain the suppressive mechanisms involved, several stud-
ies confirmed that MDSCs overexpressed Arg-1 and that inhibi-
tion of arginase partially restored T cell proliferation (15, 28, 57, 
67). To date, only a few studies have evaluated the suppressive 
function of intratumoral MDSCs in different human cancers. It 
is postulated that MDSCs only acquire their suppressive function 
when activated by the TME in situ. Divergent observations have 
been described concerning MDSC suppressive activity outside 
the TME. Several studies (Table 2) report that circulating MDSCs 
could inhibit T cell proliferation. However, all studies that directly 
compared the suppressive activity of circulating MDCS with that 
of infiltrating MDSC, only the latter exhibited significant sup-
pressive potential (15, 26, 58, 62).
Signal transducer and activator of transcription 3 is instru-
mental in the regulation of myeloid cell function. Importantly, 
STAT3 transactivation controls critical MDSC functions includ-
ing the expression of arginase. The ablation of STAT3 signaling 
diminished the suppressive function of M-MDSC by decreasing 
the enzymatic activity of Arg-1 (15). Currently, there is a phase 
1 clinical trial registered that is aimed at inhibiting Arg-1 in 
patients with solid tumors (Table 3).
More recently, a human in vitro model of monocyte-derived 
MDSCs (mo-MDSC) was shown to inhibit natural killer cell 
function independent of arginase activity. The suppressive activ-
ity exerted by these monocytes was mediated by TGF-β-induced 
PGE2 (117). Overall, these finding indicate that myeloid cells 
can block an effective T cell response by altering the amino acid 
composition of the TME in favor of tumor evasion.
PD-1/PD-L1
Targeting the PD-1/PD-L1 pathway has shown dramatic anti-
tumor effects in clinical trials, and drugs targeting this pathway 
have been approved for use in many tumor types (118–121). 
Engagement of PD-L1 on the neoplastic cells with PD-1 on 
activated T cells delivers an inhibitory signal that impairs T cell 
proliferation. In addition, PD-1 ligation alters the metabolic pro-
file of activated T cells by inhibiting glycolysis in favor of fatty acid 
oxidation preventing effector cell development (122). Interfering 
with PD-L1 or PD-1 can block the suppressive signal delivered 
to the T cell causing a reboot of the immune response. Clinical 
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studies have shown that PD-L1 expression by tumor epithelium 
correlates with a positive response to PD-1/PD-L1 inhibition 
(123). However, it is now emerging that tumor-resident myeloid 
cells in some cancers also express PD-L1 (86).
Our understanding of the mechanism involved in the regula-
tion of PD-L1 on myeloid cells is limited. In prostate cancer, only 
soluble factors derived from stromal cells induced PD-L1 expres-
sion on monocytes, whereas epithelial soluble factors showed no 
effect (86). IL-6 was identified as an important regulator of PD-L1 
expression with the inhibition of STAT3 preventing the upregula-
tion of PD-L1 (86). Despite this, IL-10 did not appear to play a 
role in PD-L1 regulation under these experimental conditions. 
In tumor-bearing mice, hypoxia-induced PD-L1 expression on 
MDSCs, macrophages, and tumor cells in a hypoxia-inducible 
factor-1α-dependent manner (124). It is clear that the regulation 
of PD-L1 expression is complex and that multiple regulatory 
pathways within the TME are at play. Thus, elucidating the 
mechanisms regulating PD-L1 expression in the tumor will 
hopefully enable the development of better companion biomark-
ers to predict response to therapies targeting the PD-1/PDL-1 
interaction.
MeCHANiSMS BY wHiCH MYeLOiD CeLL 
SUPPORT TUMOR CeLL iNvASiON
Beyond immune suppression, myeloid cells can provide support 
to neoplastic cells enabling their invasion and migration by 
enhancing EMT changes. The EMT process converts neoplastic 
cells into motile and invasive mesenchymal cells allowing them 
to invade the surrounding stroma and seed in distant sites. This 
process is essential for metastasis. Evidence is emerging that 
myeloid cells participate in this process at both the initiation and 
invasion stage (125).
In breast cancer, a GM-CSF-CCL18-positive feedback loop 
was identified as an important mechanism in sustaining EMT 
and metastasis of cancer cells. GM-CSF derived from cancer 
cells induced neighboring macrophages to produce CCL18, 
which in turn caused mesenchymal-like changes of cancer 
cells through the activation of NF-κβ (126). Interestingly, the 
authors demonstrated that GM-CSF and CCL18 were both 
highly expressed at the invasive front of tissue sections, which 
were associated with a more advanced histological grade. Also in 
breast cancer, a subpopulation of highly motile MENAINV cancer 
cells co-migrated with macrophages toward blood vessels in an 
EGF-dependent manner. MENA expression localized in cancer 
cells located at metastatic sites called tumor microenvironment of 
metastasis. These sites positively correlated with metastatic out-
come in patients. Furthermore, in vitro assays demonstrated that 
cancer cells that migrated through a layer of human endothelial 
cells were enriched with MENAINV and that intravasation was 
significantly enhanced in the presence of macrophages (127). In 
addition, an accumulation of c-Met+ monocytes at the invasive 
tumor front was associated with vascular invasion and poor 
prognosis in HCC. The author reported that these monocytes 
produced MMP-9 in response to stromal-derived HGF-9 (128). 
This suggests that these cells may contribute to tumor progression 
via the degradation of the extracellular matrix supporting cancer 
cell invasion.
In keeping with the idea that MDSCs can promote metastasis, 
several studies have shown that patients with extensive meta-
static tumor burden present with higher numbers of MDSCs (5, 
15, 58). Furthermore, MDSC frequency decreased in response 
to neoadjuvant therapy (129). Several human studies have 
investigated the mechanism by which MDSCs can shape the 
tumor phenotype. Aldehyde dehydrogenase 1 (ALDH1) is an 
important marker of cancer stem cells (CSCs). Tumors from 
patients with pancreatic cancer that expressed high levels of 
ALDH1 were associated with poor overall survival. The same 
study found that in vitro generated mo-MDSC increased ALDH1 
bright CSCs in a co-culture system (28), which was reversible by 
blocking STAT3.
Similarly in ovarian cancer, human MDSC isolated from the 
TME were capable of fostering and maintaining ALDH expres-
sion within the CSC pool (26) CD33hi MDSCs stimulated the 
upregulation of microRNA101 in ovarian cancer cells that in turn 
targets cell stemness repressor gene C-terminal binding protein 
(CtBP) 2. The clinical relevance of this was demonstrated in those 
patients who had tumors with the highest levels of CD33hi cell 
infiltration, and the lowest levels of CtBP2 expression experienced 
a shorter overall survival.
Collectively these studies show that myeloid cells appear to be 
educated by the TME so that they adapt a trophic role that allows 
the tumor to express its full neoplastic potential.
CONCLUSiON
Tumor-resident myeloid cells are both phenotypically and func-
tionally diverse cells. Much remains to be understood about how 
they evolve and function within the TME. Most importantly how 
they co-operate with tumor-resident lymphocytes to regulate 
antitumor immunity. The recent revolution in therapeutics, tar-
geting immune checkpoint inhibitors, demonstrates that durable 
and complete remission is possible when the immune system 
is reactivated appropriately. To hasten the progress of myeloid 
cell-targeted therapies to the clinics, cancer immunologists need 
to make a concerted effort to delineate how phenotype relates 
to function within the entire diverse myeloid cell lineage. The 
identification and targeting of the key pathways that regulate 
myeloid cell function will allow the design of more efficacious 
immunotherapies.
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